endocrine toxicity of immune checkpoint inhibitors

What is it about?

adverse events of new cancer thérapies are still in the process of description. Clinical trials poorly describe the reported adverse event so that their frequency is far from perfectly known and their management is not standardized. Moreover, recommendations usually propose to decide for hormonal supplementation according to clinical symptoms, which may be unspecific and hard to identify among those related to the disease itself.

Featured Image

Why is it important?

screening for this kind of toxicity is not standardized and there is a risk of overlooking symptoms impairing quality of life, as well as lifethreatening complications. Furthermore, appropriate management usually allows for continuation of important and efficient thérapies.

Perspectives